S&P/ASX 200 (INDEXASX:XJO) tracks lower: Liontown Resources Ltd (ASX:LTR) suitor walks
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.35% to 7026.50.
Looking to broaden your horizons, diversify your portfolio and invest in the mighty US stock market? Here are the latest US stock ideas, stories and news from our team at Rask Media, covering companies on the two largest stock exchanges in the world: the New York Stock Exchange (NYSE) and the NASDAQ.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.35% to 7026.50.
Some people love the stock market. But they are few and far between, you only hear about the winners, and most of you will only ever visit the activity, find out its too much work, too painful, too costly, too damaging to your relationship, and you move on.
Aussie borrowers with living expenses exceeding income hit 13% in July 2023, up from just 3% in April 2022 for those on variable rates.
The local highlight this week will be Thursday’s September employment report, with a further solid 20k gain in employment expected, which should keep the unemployment rate steady at 3.7%.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.68% to 7088.40.
In a higher rate environment with equities offering an underwhelming risk premium, many are questioning whether equities still offer much capital growth upside.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +1.01% to 7040.60.
Sonic Healthcare Ltd (ASX: SHL) has traditionally viewed as an ASX share that provides a mixture of dividends and defensive growth for investors. However, SHL shares have been sold off 17% over the last 6 months.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.23% to 6970.20.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.35% to 7026.50.
Some people love the stock market. But they are few and far between, you only hear about the winners, and most of you will only ever visit the activity, find out its too much work, too painful, too costly, too damaging to your relationship, and you move on.
Aussie borrowers with living expenses exceeding income hit 13% in July 2023, up from just 3% in April 2022 for those on variable rates.
The local highlight this week will be Thursday’s September employment report, with a further solid 20k gain in employment expected, which should keep the unemployment rate steady at 3.7%.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.68% to 7088.40.
In a higher rate environment with equities offering an underwhelming risk premium, many are questioning whether equities still offer much capital growth upside.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +1.01% to 7040.60.
Sonic Healthcare Ltd (ASX: SHL) has traditionally viewed as an ASX share that provides a mixture of dividends and defensive growth for investors. However, SHL shares have been sold off 17% over the last 6 months.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.23% to 6970.20.
Want to level-up your analytical skills and investing insights but don’t know where to start? We can help. Join 40,000+ Australian investors on our mailing list today and we’ll send you our favourite podcasts, courses, resources, investment articles and podcasts every week. Delivered to your inbox every Sunday morning. Grab a coffee and let Owen and the team bring you the best investment insights every week.
The information on this website is general financial advice only. That means, the advice does not take into account your objectives, financial situation or needs. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. In addition, you should obtain and read the product disclosure statement (PDS) and Target Market Determination before making a decision to acquire any financial product. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. Please read our Terms & Conditions and Financial Services Guide before using this website.
“Rask Invest” is considered a financial product and has a Product Disclosure Statement (PDS) and Target Market Determination (TMD), issued by InvestSMART. These documents can be accessed on the Rask Invest website. Please seek professional advice before making any investment decision with respect to Rask Invest.
© Rask Australia 2024